CN Patent

CN102224141B — N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺的固体形式

Assigned to Vertex Pharmaceuticals Inc · Expires 2014-10-08 · 12y expired

What this patent protects

本发明涉及N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1，4-二氢喹啉-3-甲酰胺的固态形式(例如晶型)、包含其的药物组合物及使用其的方法。

USPTO Abstract

本发明涉及N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1，4-二氢喹啉-3-甲酰胺的固态形式(例如晶型)、包含其的药物组合物及使用其的方法。

Drugs covered by this patent

Kalydeco (IVACAFTOR) · Vertex Pharms Inc

Patent Metadata

Patent number: CN102224141B
Jurisdiction: CN
Classification: —
Expires: 2014-10-08
Drug substance claim: No
Drug product claim: No
Assignee: Vertex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.